TY - JOUR
T1 - Lupus-associated protein losing enteropathy (LUPLE) complicated by a hypercoagulable state and successfully treated with belimumab
AU - Lewis, Justin S.
AU - Sharma, Anil
AU - Horton, Joel B.
AU - Deodhar, Atul
AU - Modiano, Nir
N1 - Publisher Copyright:
© 2020, Japanese Society of Gastroenterology.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Protein-losing enteropathy (PLE) is a condition characterized by gut mucosal injury that typically manifests with edema and hypoalbuminemia due to protein loss in the GI tract. We present a rare case of lupus-associated PLE (LUPLE) manifested by profound edema, diarrhea, and thrombotic complications. Through our case report, we discuss the typical clinical presentation, diagnostic studies available, and treatment options for these patients. Our patient’s clinical picture and laboratory markers improved with the initiation of corticosteroids and belimumab, which is a novel treatment regimen for LUPLE. Moreover, our patient was found to have a clinically significant hypercoagulable state that was ultimately attributed to PLE in the setting of systemic lupus erythematosus (SLE). We highlight the increased thrombotic risk in these patients and the subsequent management implications with regard to anticoagulation. Gastroenterologists are likely to be involved in the care of these patients, and may be the first to recognize the constellation of findings in PLE, leading to potentially very effective treatment.
AB - Protein-losing enteropathy (PLE) is a condition characterized by gut mucosal injury that typically manifests with edema and hypoalbuminemia due to protein loss in the GI tract. We present a rare case of lupus-associated PLE (LUPLE) manifested by profound edema, diarrhea, and thrombotic complications. Through our case report, we discuss the typical clinical presentation, diagnostic studies available, and treatment options for these patients. Our patient’s clinical picture and laboratory markers improved with the initiation of corticosteroids and belimumab, which is a novel treatment regimen for LUPLE. Moreover, our patient was found to have a clinically significant hypercoagulable state that was ultimately attributed to PLE in the setting of systemic lupus erythematosus (SLE). We highlight the increased thrombotic risk in these patients and the subsequent management implications with regard to anticoagulation. Gastroenterologists are likely to be involved in the care of these patients, and may be the first to recognize the constellation of findings in PLE, leading to potentially very effective treatment.
KW - Belimumab
KW - Hypercoagulable state
KW - Hypoalbuminemia
KW - Protein-losing enteropathy
KW - Systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=85088789237&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088789237&partnerID=8YFLogxK
U2 - 10.1007/s12328-020-01186-5
DO - 10.1007/s12328-020-01186-5
M3 - Article
C2 - 32734316
AN - SCOPUS:85088789237
SN - 1865-7257
VL - 13
SP - 771
EP - 774
JO - Clinical Journal of Gastroenterology
JF - Clinical Journal of Gastroenterology
IS - 5
ER -